January 2016 in “한국공업화학회 연구논문 초록집” The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
13 citations
,
December 2008 in “Veterinary dermatology” A rabbit with sebaceous adenitis was effectively treated with ciclosporin and medium-chain triglycerides.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
17 citations
,
February 1989 in “Fertility and sterility” Cimetidine did not reduce hair growth in women with hirsutism.
January 2017 in “Anais do 5º Encontro Brasileiro para Inovação Terapêutica” The oils showed potential to kill certain cancer cells, especially from Dysphania ambrosioides.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
July 2023 in “Panacea Journal of Medical Sciences” Chemotherapy often causes skin, hair, and nail problems in cancer patients.
1108 citations
,
January 2018 in “Dalton transactions” Platinum-based chemotherapy drugs can cause many severe side effects, often requiring dose reductions and additional medications to manage.
3 citations
,
October 2024 in “Cancers” Skin side effects from melanoma immunotherapy are common and may indicate better survival.
April 2022 in “Anti-cancer agents in medicinal chemistry” Some existing medicines show promise as safe treatments to protect against the side effects of radiation therapy.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
39 citations
,
October 2014 in “Schweizerische medizinische Wochenschrift” Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.
January 2018 in “Journal of the advanced practitioner in oncology” Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
December 2023 in “Journal of Thoracic Disease” Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.
5 citations
,
June 2022 in “Journal of Oncology” Blocking the Hedgehog pathway may help overcome drug resistance in multiple myeloma.
September 2019 in “Pakistan Journal of Pharmaceutical Sciences” Combining pemetrexed with platinum drugs improves treatment outcomes and quality of life for elderly patients with advanced lung adenocarcinoma.
86 citations
,
November 2020 in “Annals of Oncology” Early intervention and tailored management can reduce skin side effects from cancer treatments.
44 citations
,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.